POLISCOPE
Back to feed
FEDERALhearing transcript

Update on 21st Century Cures Act Implementation

Original title: 21ST CENTURY CURES IMPLEMENTATION: UPDATES FROM FDA AND NIH

January 1, 2019

Track this bill to get notified when it advances a stage. One tap to stop, anytime.

The Frame

What this does

The hearing tracks the implementation of a major federal law that dictates how the FDA and NIH allocate resources and regulate medical innovation, directly impacting the speed and safety of new drug and treatment approvals.

Who is mentioned in the record

Potentially affected actors named in the source documents. Mention is not a position.

FDA

The agency is responsible for implementing regulatory changes mandated by the 21st Century Cures Act.

NIH

The agency is responsible for executing research initiatives funded or authorized by the 21st Century Cures Act.

What changed

Last recorded activity January 1, 2019.

What's next

Next step not available in the current record.

Summary

This document is the transcript of a 2018 House hearing regarding the progress of the . Federal officials from the FDA and NIH provided updates on how the law is being implemented to advance medical research and drug regulation.

Key Facts

  • The hearing was held on July 25, 2018, to review the implementation of the 21st Century Cures Act.
  • The Subcommittee on Health of the Committee on Energy and Commerce presided over the hearing.
  • Witnesses included the Director of the NIH and the Commissioner of the FDA.
  • The hearing included testimony from the Deputy Director of the 'All of Us' Research Program and the Director of the National Cancer Institute.

Frequently Asked Questions

What is the purpose of this hearing?
The hearing was held to receive updates from the FDA and NIH on how they are implementing the provisions of the .
Who testified at this hearing?
The witnesses included Francis Collins (Director of the NIH), Scott Gottlieb (Commissioner of the FDA), Stephanie Devaney (Deputy Director of the All of Us Research Program), and Norman Sharpless (Director of the National Cancer Institute).

Why It Matters

The hearing tracks the implementation of a major federal law that dictates how the FDA and NIH allocate resources and regulate medical innovation, directly impacting the speed and safety of new drug and treatment approvals.

News Coverage

No news coverage found yet. Articles are indexed twice daily.

Sponsors

Discoveries

Patterns POLISCOPE noticed across the record. These are observations to investigate, not conclusions.

policy shift90% confidence

Cures Act Oversight

The hearing demonstrates the ongoing congressional oversight required to ensure federal agencies align their operations with the 21st Century Cures Act mandates.

Connected Entities

personFrancis CollinsDirector of the National Institutes of Health (NIH)Map →
personScott GottliebCommissioner of the Food and Drug Administration (FDA)Map →
organizationHouse Subcommittee on HealthCommittee overseeing the hearingMap →
personMichael C. BurgessChairman of the Subcommittee on HealthMap →
personNorman SharplessDirector of the National Cancer InstituteMap →
personStephanie DevaneyDeputy Director, All of Us Research ProgramMap →

Sources

Open source document

www.govinfo.gov

Analysis Score

0–100
  • Significance60
    How much this matters to a regular citizen
  • Controversy10
    Intensity of disagreement among stakeholders
  • Entertainment5
    Compellingness for a non-policy-wonk reader
  • Buzz10
    Current news / social attention level

Publisher tools

Share or embed this record

POLISCOPE publisher tools

Share or embed this record